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ABSTRACT: Previously we proposed a heparin/protamine-based system for delivery of
protease drugs such as tissue-specific plasminogen activator (tPA). To demonstrate the
feasibility of this approach as well as its pro-drug and triggered release features, posi-
tively charged peptides [(Arg)7Cys] were successfully linked to tissue-specific plasmin-
ogen activator (tPA) using the crosslinking agent N-succinimidyl-3-(2-pyridyldithio)-
propionate. This cation-modified tPA showed much stronger heparin affinity than the
parent tPA. The complex formed by mtPA and heparin was stable in human plasma,
and the activity of mtPA in such a complex was inhibited by the appended heparin.
Similarly, the activity of mtPA could also be inhibited by a heparin-antifibrin IgG
conjugate in which heparin was linked, via endpoint attachment, to the sugar moieties
in the Fc region of anti-fibrin IgG. Aside from this pro-drug feature exhibited by the
binding of the macromolecule heparin to mtPA, results from chromogenic and in vitro
clot lysis assay demonstrated that the heparin-induced inhibition of the mtPA activity
could be easily reversed by the addition of an adequate amount of protamine. These
findings suggest the applicability of the heparin/protamine delivery system to abort the
potential bleeding risks associated with clinical use of tPA. In addition to the chemical
conjugation method, modified tPA could also be produced by the recombinant
DNA method. The expressed modified tPA (EmtPA) thus prepared retained the full
catalytic activity of the parent tPA, and this activity could also be inhibited by heparin,
and the heparin-induced inhibition could be reversed following the addition of pro-
tamine. © 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci
89: 664–673, 2000
INTRODUCTION
The primary reasons for the lack of clinical appli-
cation of enzymes lie in their potential immuno-
genicity as well as their indiscriminate actions
toward both target and normal substrates. To re-
duce the immunogenicity and increase the life
span of enzymes, much effort has been directed
toward chemically modifying the enzyme with
dextran, albumin, and polyethylene glycol, etc., or
encapsulating the enzyme in human red blood
cells.1–4 It has been proven that such chemical
modifications and red cell encapsulation are effec-
tive in improving the pharmacokinetic profile and
decreasing the immunogenicity of enzymes. The
inability of an enzyme to distinguish between the
target and normal substrates, however, will yield
unwanted toxic effects. This still stands as the
major hurdle to the use of enzymes as clinical
drugs. Take thrombolytic agents as an example.
These agents are plasminogen activators (PA)
that are widely used in clinical treatment of es-
tablished thrombus in myocardial infarction and
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pulmonary embolism. However, all these agents
activate both fibrin-bound and circulating plas-
minogen indiscriminately. This activation of cir-
culating plasminogen results in the systemic re-
lease of excess plasmin leading to the so-called
“lytic state” manifested by marked depletion of
a2-antiplasmin, fibrinogen, and other coagulation
proteins. Although several approaches have been
attempted to solve this problem,5,6 current throm-
bolytic therapy is still beset by a high incidence of
bleeding complications.
Previously, we reported the development of a
novel heparin/protamine-based enzyme delivery
system that could be used to deliver a PA drug
without this associated bleeding risk.7 As shown
in Figure 1, this system comprises of a large com-
plex made of two components: (i) a targeting com-
ponent consisting of an antibody chemically
linked with an anionic heparin molecule and (ii) a
drug component consisting of the PA drug modi-
fied with cationic species. Because the used cat-
ions are relatively small (e.g., a small positively
charged peptide), the modified PA should be able
to retain a significant level of its proteolytic ac-
tivity. The modified PA, however, would be de-
prived of such an activity once it binds to the an-
tibody/heparin counterpart, presumably due to
blocking of the PA’s active sites by these ap-
pended macromolecules. The two components can
be linked automatically via a tight but reversible
electrostatic interaction. Therefore, similar to a
“pro-drug” type approach, the modified PA would
be without proteolytic activity during administra-
tion, thereby alleviating the bleeding risk intro-
duced by systemic activation of circulating plas-
minogen. Following the targeting of the thrombus
by the attached anti-fibrin antibody, the “active”
modified-PA can be locally released at the sites of
the clot by using a triggering agent such as prot-
amine; which is the clinical heparin antagonist
known to bind heparin stronger than most cat-
ionic species.
In this paper, we present a review of our recent
research on the demonstration of the feasiblity of
the heparin/protamine delivery system in deliv-
ery of thrombolytic agent. A poly(Arg)7 peptide
was linked, via both chemical and biological
means, to a tPA molecule to produce the cation-
modified drug.8,9 A novel conjugation method was
established to attach heparin, via its reducing
end, to the Fc region of antifibrin antibody.
9 This
heparin anti-fibrin IgG conjugate fully retained
the function of heparin for binding and of the an-
tibody for targeting. The pro-drug and triggered
release features of the delivery system were suc-




Recombinant tPA (Alteplase) was purchased from
Genentech Inc (South San Francisco, CA). The
chromogenic substrates D-Val-leu-lys-p-nitro-
Figure 1. Schematic diagram of the proposed ap-
proach.
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anilide (S-2251) was purchased from Pharmacia
Hepar Inc. (Franklin, OH). Murine anti-fibrin
and anti-tPA IgG was from American Diagnostica
Inc. (Greenwich, CT). The double-stranded oligo-
nucleotide used for expressing poly(Arg)7 was:
58 CGCCGTCGACGGCGCAGAAGGCGCGGCG-
GCAGCTGCCGCGTCTTCCGCGCCGGC, which
contained two NarI restriction enzyme sites at
the two ends and one SalI site in between the
sequence, was synthesized and purified by Inte-
grated DNA Technologies (Coralville, IA). Plas-
mid PtPA-trp12 for expression of tPA in Esch-
erichia coli and bacterial strains HB101, RB791
were obtained from ATCC (American Type Cul-
ture Collection, Rockville, MD). Other regents
were from Sigma (St. Louis, MO).
Preparation and Purification of the tPA/(Arg)7Cys
(Arg)7Cys and tPA were linked with the heterobi-
functional crosslinking reagent SPDP using a
two-step procedure described previously.10 A
schematic description of the conjugation between
(Arg)7Cys and tPA was included in Figure 2A.
The reaction mixture was passed through a Seph-
adex G-25 column to remove non-reacted re-
agents. Modified tPA, termed mtPA, was sepa-
rated from tPA through passing a heparin–
Sephadex column (5 × 0.5 cm).
Preparation of Heparin/Anti-fibrin IgG Conjugate
Heparin (1.0 g) and the sugar moieties on anti-
fibrin IgG was oxidized by sodium nitrite and
NaIO4, respectively, to produce aldehyde groups.
A detailed description of the chemical conjugation
between heparin and anti-fibrin IgG was illus-
trated in Figure 2B. The heparin/anti-fibrin IgG
conjugates were purified by passing through a
protamine–Sepharose column and eluting with
2.0 M NaCl. The anti-fibrin activity of heparin/




Plasminogen activation was determined by moni-
toring the production of plasmin using its specific
substrate S-2251 according to the procedure de-
scribed previously.11 The initial rate of S-2251 hy-
drolysis was estimated by measuring the absor-
bance at 405 nm at different time intervals in a
micro-plate reader (BioRad, Hercules, CA), and
was expressed as A405/min
2.
Fibrin Clot Lysis Assay
The activity of tPA was determined by fibrin clot
lysis assay using fibrin-containing agarose plates.
Figure 2. Schematic diagram of the synthesis of (A) modified tPA and (B) the heparin/anti-fibrin IgG conjugate.
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The plates were prepared as follows: 5.0 mL of
low melting temperature agarose solution (3.0%,
in TBS) containing 2.5 U thrombin was mixed
with 5.0 mL of solution containing fibrinogen (5
mg/mL) at 37°C. The reaction mixtures were
poured into a 90 mm culture dish and incubated
at 37°C for 30 min until the fibrin clot became
visible. To perform the assays, samples were
added directly into the 3-mm sample wells made
on the solidified fibrin–agarose gel and incubated
at 30°C for overnight. The degree of clot lysis was
then estimated by analyzing the size of the fibrin
lysis zone around these 3-mm wells.
Binding of tPA (or mtPA) to
Heparin–Sepharose Beads
Solutions (0.1 mL) of tPA (or mtPA) in TBS were
mixed with 0.02 mL of heparin–Sephadex beads
and incubated at room temperature for 5 min.
The heparin–Sephadex beads were then rinsed
with 0.1 mL of plasma for 5 min, followed by ad-
ditional washing with plasma (twice) and TBS
(twice). The total amount of tPA (or mtPA) activ-
ity adsorbed to the heparin beads was determined
by eluting the beads with 2.0 M NaCl. The per-
centage of inhibition of tPA (or mtPA) activity
was estimated from the ratio of the tPA (or mtPA)
activity adsorbed to and de-sorbed from the hep-
arin beads.
Assay of Plasminogen, a2-Antiplasmin and
Fibrinogen Levels in Plasma
Plasminogen and a2-antiplasmin levels in plasma
were determined according to the method de-
scribed previously.12 Fibrinogen level in plasma
was estimated by determining activated partial
thromboplastin time (APTT), which is inversely
proportional to the fibrinogen concentration. In
brief, thrombin of 500 U/mL (150 mL) was mixed
with 150 mL of diluted plasma and APTT was
measured using a Fibrometer (BBL FibroSystem,
Cockeysville, MD).
Construction and Identification of the Plasmid for
Expression of EmtPA in E. coli
A schematic illustration of the procedures for con-
struction of the plasmid for expression of EmtPA
is presented in Figure 3. As shown, plasmid for
expression of tPA, ptPA-trp12, was separately di-
gested with restriction enzymes EcoRI + NarI,
EcoRI + BglII, or NarI + BglII. The cleaved DNA
fragments were then isolated by agarose gel elec-
trophoresis and purified using the Nucleic Acid
Rapid Isolation Kit (Sigma). A 336-base pair (bp)
EcoRI–NarI fragment for encoding prior peptides,
a 1,700-bp NarI–BglII fragment for expression of
tPA, and a 4,200-bp vector fragment containing
trp promoter and encoding gene against antibiot-
ics were collected. These three fragments and the
above double-stranded oligonucleotide (encoding
the poly(Arg)7 sequence) were linked in order us-
ing T4 ligase. After ligation, the reaction mixture
was transformed into HB101 bacterial strain, and
the corresponding plasmid for expression of
EmtPA was screened and identified by the diges-
tion with restriction enzymes BglII and SalI.
Expression and Purification of EmtPA
The recombinant plasmid (ptPA-polyArg) was ex-
pressed in RB791 bacteria strain as previously
described.13 After they were harvested, cells were
suspended in 6 M guanidine hydrochloride (in a
volume ratio of 1:9), sonicated for 30 s, incubated
at room temperature for 30 min, and then dia-
lyzed overnight against 50 mM Tris-HCl buffer
(pH 8.0) containing 250 mM NaCl, 0.25 mM
EDTA, and 0.01% Tween 80. Then the sample
was loaded to 1 mL of HiTrap chelating column
and eluted with the buffer (0.02 M Na2HPO4, 1 M
NaCl, and 1 mM imidazole at pH 7.2) containing
a linear gradient (0–0.32 M) of imidazole. The
EmtPA fractions after chromatography were col-
lected and then concentrated using an Amicon
(Beverly, MA) concentrator.
RESULTS AND DISCUSSION
Synthesis of the tPA/(Arg)7Cys and
Heparin/Anti-fibrin IgG Conjugates
It is known that the prelude of heparin-induced
biological functions is its binding with antithrom-
bin III (ATIII). This suggests that ATIII possesses
a stronger affinity to heparin than all the other
plasma heparin-binding proteins.14 Hence, for
our approach to function properly, a pre-requisite
is that the binding of the modified-PA to heparin
must be stronger than that of ATIII but weaker
than that of protamine. This would allow the
modified-PA to remain attached to, and therefore
inhibited by the appended heparin–antibody com-
ponent following administration, and yet be dis-
sociable from this component upon protamine ad-
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ministration. Previous studies conducted in our
laboratory indicated that a low molecular weight
protamine (LMWP) fragment containing 6 or 7
arginine residues, which was prepared by diges-
tion of native protamine with thermolysin, was
able to yield a heparin-binding compount that
was stronger than that of ATIII.15 On the basis of
this finding, a peptide containing seven arginine
residues [poly(Arg)7] was attempted to produce
the cation-modified tPA with the desirable hepa-
rin-binding affinity.
Figure 2A depicts the synthesis of the tPA/
(Arg)7Cys conjugate. Approximately 40% of tPA
activity was retained following the synthesis of
this modified tPA (Table I). The major activity
loss occurred during the purification step where
the reaction mixture was purified using a heparin
column. Purification of desirable modified tPA
(mtPA) with a high salt elution in the removal of
unmodified tPA and mtPA with weak heparin-
binding affinity, resulted in a large loss in overall
tPA activity recovery. This mtPA clearly con-
tained the heparin-binding poly(Arg)7 peptides,
as the binding percentage of tPA in the prepara-
tion containing mtPA in TBS diluted plasma (1:1)
was increased to 76% compared to that of 35% in
preparation containing unmodified tPA (Table I).
Heparin was conjugated to anti-fibrin IgG via
an endpoint attachment (Figure 2B). After conju-
gation with heparin, anti-fibrin IgG showed an
increase in its molecular weight detected by SDS–
PAGE (Table II). The molar ratio between hepa-
Figure 3. Schematic description of the construction of the recombinant PtPA-polyArg plasmid for expression of
EmtPA.
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rin and IgG in the heparin–IgG conjugate esti-
mated by the molecular weight was consistent
with that determined using azure-A and Coo-
massie Blue for heparin and protein quantifica-
tion, respectively (Table II). Based on an average
molecular mass of 15 kDa for heparin, it was es-
timated that each anti-fibrin IgG was conjugated
with approximately 1 or 2 heparin molecules. The
anti-fibrin IgG in such heparin/anti-fibrin IgG
conjugates retained nearly 80% of its original fi-
brin-binding ability determined by ELISA (data
not shown).
Characterization of the tPA/(Arg)7Cys
To determine if modified tPA still retained its
catalytic functions, the plasmin activity produced
by the mtPA-mediated plasminogen activation
was measured using substrate S-2251. Compared
with the specific activity of 5,800 IU/mg protein of
the unmodified tPA, the amidolytic activity of
mtPA was estimated to be 3,900 IU/mg protein.
The Km value for mtPA (2.7 mM) was higher than
that for tPA (1.1 mM), whereas the Km/kcat data
for mtPA (18.2 mM−1 min−1) and tPA (26.4 mM−1
min−1) were relatively comparable (Figure 4A).
It is well recognized that fibrin selectivity is
the major reason for the preferred use of tPA over
other clinical thrombolytic agents. Research in
the past has thoroughly demonstrated that the
activity of tPA was greatly enhanced in the pres-
ence of fibrin(ogen). As shown in Figure 4B, like
tPA, the mtPA-mediated plasminogen activation
was also enhanced in the presence of fibrinogen,
implying that mtPA still retained a similar re-
sponse to fibrinogen as that of the parent tPA,
and modification of tPA with the (Arg)7Cys did
not result in significant changes in the fibrin-
binding ability of tPA.
Characterization of the Pro-drug Feature of the
Heparin/Protamine-Based mtPA Delivery System
Immobilized heprin was used to mimic the mac-
romolecular nature of the proposed heparin–IgG
conjugate. To examine the pro-drug feature of the
heparin/protamine-based mtPA delivery system,
the amidolytic activity of tPA and mtPA bound on
the heparin beads were compared. Sepharose
beads containing immobilized heparin were
added to the tPA or mtPA solution. To avoid any
influences from loosely-bound tPA or mtPA (due
to insufficient modification by the poly(Arg)7 pep-
tides), the tPA- or mtPA-bound heparin beads
were rinsed three times with plasma. As shown in
Table III, after extensive washing, less than 3% of
tPA remained bound to the heparin beads com-
pared to the level of 25% for mtPA. It was note-
worthy that as much as 95% of the amidolytic
activity of mtPA were inhibited once they were
adsorbed to the heparin beads (Table III); an in-
dication of the feasibility of the pro-drug feature
of the heparin/protamine-based delivery system.
In agreement with this finding, although a sig-
nificant increase in plasmin and decrease in fi-
brinogen and plasminogen concentrations were
observed when free mtPA was added into plasma,
there were almost no statistically significant
changes in plasma plasminogen and plasmin lev-
els when the same amount of heparin-bound
mtPA was added (Table IV). Since fibrinogen con-
centration was determined by APTT and the pres-
ence of heparin would cause an increase in APTT,







Heparin/IgG 175 1.3 ± 0.4
a NA, not applicable.










Recovery of total tPA activity ∼100 91 ± 6 36 ± 12
Binding to heparin beadsa 35 ± 4 52 ± 12 76 ± 3
a Binding percentage of tPA activity to heparin beads measured in TBS diluted human plasma (1:1) dilution.
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the slight decrease of fibrinogen concentration us-
ing the heparin-bound mtPA could be attributed
to heparin-prolonged APTT and not necessarily to
a real decrease in plasma fibrinogen concentra-
tion. The presence of nearly a similar decrease in
fibrinogen concentration in plasma treated with
heparin beads only (data not shown) provided
support to this assumption.
To further examine the pro-drug and triggered
release features of this heparin/protamine-based
tPA delivery system, the in vitro fibrin clot lysis
assay was performed. As shown in Figure 5,
mtPA adsorbed to the heparin beads (Well 6)
yielded relatively insignificant clot lysis (<5%)
compared to that of free mtPA (Well 5). When
protamine was added to the bead-bound mtPA
(see Well 7), the degree of clot lysis increased,
indicating that heparin-induced inhibition on the
mtPA activity was reversed. These results were
consistent with those seen in Table III where
chromogenic assay was used. Based on these find-
ings, it is clear that heparin can induce inhibition
on the activity of mtPA via its binding to mtPA
(i.e., the pro-drug feature), and this inhibition can
be reversed by the addition of the triggering agent
protamine (i.e., triggered release feature).
As discussed previously, the success of the dis-
cussed heparin/protamine-based delivery system
relies on two key binding conditions. One is that
the binding of mtPA to heparin has to be stronger
than that of anti-thrombin III so that mtPA can
remain attached to heparin following administra-
tion. The other requirement is that the binding of
mtPA to heparin should be weaker than that of
protamine so that heparin-induced inhibition on
mtPA can be reversed by the addition of prot-
amine. Previous studies conducted in our labora-
tory have demonstrated that the binding of
poly(Arg)7 to heparin is stronger than that of anti-
thrombin III.15 Our current results obtained us-
ing the chromogenic assay (Table III) and the fi-
Table III. Comparison Between tPA and mtPA on
Binding to Heparin, Activity Inhibition by Heparin,
and Activity Recovery by Protamine (2 mg/mL)
in Plasma
Percentage tPA mtPA
Binding to heparin beads <3 25 ± 6
Activity inhibition by binding
to heparin beads NAa 95 ± 4
Activity recovered by reversal
of heparin inhibition by protamine NA 42 ± 15
a NA, not applicable.
Table IV. Changes (%) in Plasminogen, Plasmin,
and Fibrinogen Levels in Plasma After 12 h of
Incubation With the Same Amount (1.3 mg/mL) of
Free mtPA or Bead-Adsorbed mtPA
Plasminogen Plasmin Fibrinogen
Free mtPA 62 ± 3 120 ± 4 61 ± 8
mtPA on
heparin beads 95 ± 4 102 ± 2 89 ± 10
Figure 4. Characterizations of modified tPA. (A)
Double-reciprocal plots for tPA and mtPA-mediated
plasminogen activation. (B) Effects of fibrinogen on tPA
or mtPA-mediated plasminogen activation. Experimen-
tal conditions were described in detail in the text. Rates
of conversion of plasminogen to plasmin by tPA or
mtPA were measured using small chromogenic sub-
strate S-2251.
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brin clot lysis assay (Figure 5) have also shown
that heparin-induced blockage of mtPA activity
can be partially reversed by protamine. Since the
binding strength of poly(Arg)7 to heparin is com-
parable to that of protamine,16 the concentration
of protamine used for the release of mtPA from its
adsorbed heparin counterpart is crucial to the re-
versal of heparin-induced inhibition on mtPA; as
protamine at low concentrations may not be suf-
ficient to completely dissociate mtPA from hepa-
rin binding. In addition, our recent studies using
the chromogenic assay showed that at high con-
centrations, protamine actually inhibited tPA-
mediated conversion of plasminogen to plasmin
(data not shown). Therefore, the lack of a 100%
reversal of mtPA activity in our experiments may
simply be due to the use of an inadequate amount
of protamine for heparin reversal. To this end,
more careful consideration of the heparin-binding
affinity of the positively charged peptide (i.e.,
with the required heparin-binding strengths) is
deemed necessary to achieve the success of utiliz-
ing the heparin/protamine-based system for tPA
delivery.
As proposed in our delivery system (Figure 1),
an heparin/anti-fibrin antibody conjugate was
used to enhance the targeting ability of the mtPA/
heparin pro-drug conjugate. Results in Figure 6
show that like heparin beads, the heparin/anti-
fibrin IgG conjugate was also capable of inhibit-
ing the activity of mtPA, although this inhibition
was considerably lower than that by the heparin
beads (>95%). It should be pointed out that in
those experiments involving the heparin beads,
only mtPA that bound strongly to the heparin
beads (25% of total mtPA) were used. In contrast,
in experiments involving the anti-fibrin/heparin
conjugates, different mtPA species, with or with-
out the sufficient heparin binding affinity, were
all used in the study. Because of this lack of sepa-
ration, mtPA species that were unable to bind to
the heparin/anti-fibrin IgG conjugate and there-
fore present in the reaction mixture could exert
plasminogen activation activity and, as a conse-
quence, might contribute to the observed less in-
hibition by the heparin/anti-fibrin IgG conju-
gates.
Production of Modified tPA Using Constructed
mtPA-Expressing Vector
Despite promise, however, the chemical conjuga-
tion method used previously in the preparation of
mtPA was beset by a number of limitations. One
is that this method was complicated and difficult
to control. The produced final product was hetero-
geneous and contained tPA–peptide conjugates
with a broad variety of heparin-binding affinities.
As a consequence, the yield of the tPA-peptide
conjugate with desired heparin-binding strength
was relatively low; normally in the range of 30%.
In addition, the chemical method resulted in ran-
dom incorporation of the peptides onto the tPA
Figure 5. In vitro clot lysis assay. Experimental con-
ditions were described in detail in the text. Wells 1–4
contain 0.025, 0.05, 0.1, and 0.2 mg of tPA respectively;
Well 5 contains 0.2 mg mtPA; Well 6 contains 0.2 mg
mtPA bound to heparin beads; Well 7 contains 0.2 mg
mtPA released from heparin beads by 50 mg protamine;
Well 8 contains buffer only.
Figure 6. Inhibition of mtPA activity by the heparin/
anti-fibrin IgG conjugate and reversal of inhibition by
protamine. The amidolytic activity of mtPA was mea-
sured using chromogenic substrate S-2251. Experimen-
tal conditions: mtPA, 0.5 mg/mL; plasminogen, 0.24
mM; S-2251, 1.2 mM; heparin/anti-fibrin IgG, 2 mg/mL;
protamine, 20 mg/mL.
A HEPARIN/PROTAMINE-BASED DRUG DELIVERY SYSTEM 671
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 89, NO. 5, MAY 2000
protein. While incorporation of the peptide into
folded areas of tPA would render it inaccessible to
heparin binding, incorporation onto surface re-
gions that were far away from the tPA active site
would lead to futile heparin binding that was un-
able to induce any inhibitory effects. On the other
hand, incorporation of the peptide by a recombi-
nant approach would, in principle, alleviate all
these limitations. To this regard, we also explored
the possibility of directly producing the final tPA-
peptide conjugate by using recombinant DNA
technology.
Figure 7 presents an identification of the con-
structed recombinant ptPA-polyArg plasmid. The
insertion sit of poly(Arg)7 is located at kringle I
domain of tPA to avoid any potential influence on
the thrombolytic activity and fibrin-binding abil-
ity of modified tPA.17 As shown, when digested
with restriction enzymes SalI and BglII, ptPA-
trp12 was cleaved into two fragments (Lane 2)
whereas ptPA-polyArg was cleaved into three
fragments (Lane 4). The presence of an extra
DNA band following restriction enzyme digestion
implicitly confirms that the additional SalI re-
striction enzyme site and the plasmid containing
the coding sequence of poly(Arg)7 has been prop-
erly inserted into ptPA-trp12.
Identification of the expressed tPA/poly(Arg)7
conjugate (EtPA) was conducted by the western
blot method using the anti-human tPA antibody
as the probe and the anti-goat-IgG antibody con-
jugated with alkali phosphatase as the detecting
unit. A protein band with a molecular weight
slightly higher (by about 2,000 daltons) than that
of the unmodified tPA (EtPA) and also responsive
to the anti-tPA antibody probe was observed for
the expressed protein (data not shown). Investi-
gation of the reaction kinetics using the S-2251
chromogenic assay showed that both EtPA and
EmtPA yielded almost an identical initial rate of
conversion of plasminogen to plasmin under the
same concentration.
Figure 8 shows that heparin enhanced the ami-
dolytic activity of the unmodified EtPA by about
25%. In a sharp contrast, heparin induced a sig-
nificant inhibition of the amidolytic activity of the
expressed EmtPA; on average, about 54% inhibi-
tion of its initial activity. In addition, this hepa-
rin-induced inhibition was largely reversed when
an equivalent amount of protamine (i.e., relative
to heparin) was added to the heparin and EmtPA
mixture (see Figure 8). These results strongly im-
plicate that poly(Arg)7 is present in the expressed
protein conjugate; the inhibition is simply due to
the blockage of the active site of EmtPA by the
bound heparin, and the reversal of this inhibition
is simply due to the dissociation of the bound hep-
arin by protamine.
In summary, the feasibility of the heparin/
Figure 7. Identification of the recombinant ptPA-
polyArg plasmid by restriction enzyme digestion. Lane
1, ptPA-trp12 plasmid; Lane 2, ptPA-trp12 plasmid di-
gested with SalI and BglII; Lane 3, ptPA-polyArg plas-
mid; Lane 4, ptPA-polyArg plasmid digested with SalI
and BglII; Lane 5, DNA markers.
Figure 8. Inhibition of EmtPA activity by heparin
and reversal of inhibition by protamine. Experimental
conditions: EmtPA, 0.5 mg/mL; plasminogen, 0.24 mM;
S-2251, 1.2 mM.
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protamine-based approach for tPA delivery, par-
ticularly the pro-drug and triggered release fea-
tures has been largely demonstrated in vitro. In
addition, our results also show that it is feasible
to prepare the cation-modified tPA by either
chemical or the molecular biology approach. Fur-
ther experiments are currently in progress in our
laboratory, with the ultimate goal being aimed at
demonstrating the in vivo feasibility of the pro-
posed pro-drug delivery approach in providing
targeted thrombolysis without bleeding risks.
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